The molecular genetic events underlying thyroid carcinogenesis are poorly understood. Mice harboring a knock-in dominantly negative mutant thyroid hormone receptor b (TRb PV/PV mouse) spontaneously develop follicular thyroid carcinoma similar to human thyroid cancer. Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor c (PPARc) could function as a tumor suppressor in thyroid cancer in vivo. Using the offspring from the cross of TRb PV/ þ and PPARc þ /À mice, we found that thyroid carcinogenesis progressed significantly faster in TRb PV/PV mice with PPARc insufficiency from increased cell proliferation and reduced apoptosis. Reduced PPARc protein abundance led to the activation of the nuclear factor-jB signaling pathway, resulting in the activation of cyclin D1 and repression of critical genes involved in apoptosis. Treatment of TRb PV/PV mice with a PPARc agonist, rosiglitazone, delayed the progression of thyroid carcinogenesis by decreasing cell proliferation and activation of apoptosis. These results suggest that PPARc is a critical modifier in thyroid carcinogenesis and could be tested as a therapeutic target in thyroid follicular carcinoma.
Introduction
Thyroid cancer, the most common form of endocrine malignancy, has the fastest growing incidence of all cancers in the United States, especially among women. Thyroid cancers in humans consist of an array of different histological and biological types (papillary, follicular, medullary, clear cell, anaplastic, Hurthle cell and others) (Sylvia, 2004) , but the majority of clinically important human thyroid cancers are papillary and follicular carcinomas. The most important clinical and pathological predictor in these patients is the presence of local invasion, vascular invasion or distant metastases. The molecular mechanisms underlying the initiation and progression of thyroid carcinoma are not fully understood, but it is generally believed that dysregulation of cell growth and cell death is involved.
The availability of a mouse model of follicular thyroid carcinoma has provided an opportunity to dissect the molecular basis of this cancer (Suzuki et al., 2002; Ying et al., 2003a, b) . This mutant mouse was created by a targeted mutation of thyroid hormone b receptor (TRbPV) via homologous recombination and the CreLoxP system (Kaneshige et al., 2000) . The thyroid hormone receptor b mutant (denoted as PV) was identified in a patient (PV) with resistance to thyroid hormone (RTH) (Parrilla et al., 1991) . RTH is caused by mutations of the TRb gene and manifests symptoms as a result of decreased sensitivity to the thyroid hormone (T3) in target tissues (Yen, 2003) . PV has a C-insertion at codon 448 that produces a frame shift in the carboxylterminal 14 amino acids of TRb1 (Parrilla et al., 1991) . PV has completely lost thyroid hormone (T3) binding and exhibits potent dominant-negative activity (Meier et al., 1992) . Remarkably, as homozygous TRbPV mice (TRb PV/PV mice) age, they spontaneously develop follicular thyroid carcinoma through pathological progression resembling human thyroid cancer (Suzuki et al., 2002) . One single patient homozygous for a mutant TRb has been reported and he died at a young age of unknown cause (Ono et al., 1991) . It is not clear whether RTH patients with only one mutated TRb allele have an increased incidence of thyroid cancer.
Gene expression profilings of thyroid tumors in TRb PV/PV mice have identified the repression of the peroxisome proliferator-activated receptor g (PPARg) signaling pathway as one of the altered pathways that contribute to thyroid carcinogenesis (Ying et al., 2003a) . PPARg is also a member of the nuclear hormone receptor superfamily and plays an important role in adipogenesis, cell cycle control, apoptosis and carcinogenesis (Michalik et al., 2004) . Its involvement in follicular thyroid carcinoma was demonstrated by the identification of a chromosomal rearrangement t(2;3)(q13;p25), yielding a PAX8-PPARg fusion gene in human follicular carcinomas Nikiforova et al., 2002; Cheung et al., 2003; Gustafson et al., 2003) . When fused to PAX8, PPARg not only loses its ability to stimulate thiazolidinedione-induced transcription, but also acts to inhibit PPARg transcriptional activity , raising the possibility that PPARg could act as a tumor suppressor in thyroid carcinoma.
Previously, we showed that the expression of PPARg mRNA becomes repressed in TRb PV/PV mice during thyroid carcinogenesis. Moreover, troglitazone-activated PPARg transcriptional activity is repressed by mutant PV (Ying et al., 2003b) . These findings support the proposal that PPARg could act as a tumor suppressor in thyroid carcinoma. The present study aimed to delineate the PPARg downstream molecular pathways that contribute to its tumor suppressor effects in vivo. We found that PPARg insufficiency promotes thyroid carcinogenesis in TRb PV/PV mice by increasing proliferation and decreasing apoptosis. These changes are mediated, at least in part, via activation of the nuclear factor-kB (NF-kB) signaling pathway, resulting in the activation of cyclin D1 and repression of critical genes involved in the apoptosis. These in vivo results indicate that PPARg could be tested as a potential molecular target for treatment of thyroid cancer.
Results
Lack of one allele of PPARg promotes thyroid carcinogenesis in TRb PV/PV mice To evaluate the effect of PPARg on the progression of thyroid cancer, we crossed TRb PV/ þ mice with PPARg þ /À mice to obtain offspring for phenotypic characterization. As deletion of both alleles of the PPARg gene is lethal to embryos (Akiyama et al., 2002) , we could only evaluate the effect of the lack of one allele of the PPARg gene on the development and progression of TRb PV/PV mice. Figure 1a shows that the expression of PPARg mRNA was lower in TRb þ / þ PPARg þ /À mice than in wild-type mice (bar 2 versus bar 1). Consistent with our earlier studies (Ying et al., 2003b) , the expression of PPARg mRNA in TRb PV/PV mice was B60% lower than in wild-type mice (bar 3 versus bar 1, Figure 1a ). In TRb PV/PV PPARg þ /À mice, the expression of PPARg mRNA was further reduced (bar 4; Figure 1a ). We further compared the expression of PPARg at the protein level (Figure 1b) . The PPARg protein abundance in TRb PV/PV mice was B60% lower than in wildtype mice (lanes 7-9 versus lanes 1-3 of Figure 1b and d). The lack of one PPARg allele led to a further 60% reduction as compared with TRb PV/PV PPARg þ / þ mice (lanes 10-12 versus lanes 7-9 of Figure 1b and d) . Figure 1c shows the loading controls using a-tubulin for the Western blot shown in Figure 1b . To be certain that the reduced expression of PPARg protein in TRb PV/PV mice led to the repression of the PPARg activity, we evaluated the mRNA expression of its direct downstream target gene, the lipoprotein lipase (LpL) (Schoonjans et al., 1996; Goldberg and Merkel, 2001 ).
Indeed, consistent with the protein abundance of PPARg, the expression of LpL mRNA was repressed (bars 3 and 4 versus bars 1 and 2).
Analysis of the survival curves indicates that TRb PV/PV PPARg þ /À mice died at a significantly younger age (50% survival age: 19978.5 days, n ¼ 46; Figure 2a) 
mice at the age of 3, 5 and 7 months ( Figure 2b ). The effect of the PPARg insufficiency on thyroid carcinogenesis was also evaluated by histopathological analysis. Figure 3a shows that even though not statistically different, capsular invasion had a higher tendency to occur at an increased frequency in TRb
mice than in TRb PV/PV PPARg þ / þ mice at a younger age of 3-5 months. However, this difference was lost as the mice aged. This observation suggests that as the mice age, other additional genetic changes could blunt the effect of PPARg insufficiency on this pathological manifestation. Similarly, a higher tendency in developing vascular invasion in TRb PV/PV PPARg þ /À mice at 6-12 months was also noted (Figure 3b ). Importantly, a significant 1.5-fold increase in lung metastases was observed in TRb PV/PV PPARg þ /À mice (Po0.05; Figure 3c ). Taken together, these findings suggest that PPARg insufficiency could promote thyroid carcinogenesis in TRb PV/PV PPARg þ /À mice. (Kaneshige et al., 2000; Kato et al., 2004) , total serum L-thyroxine (TT4) (Figure 4a PPARg insufficiency activates the NF-kB signaling pathway in thyroid tumors Using cDNA microarrays, we previously identified the NF-kB signaling as one of the altered pathways associated with thyroid carcinogenesis of TRb (Ying et al., 2003a) . It has recently been shown that PPARg insufficiency causes activation of the NF-kB pathway in B cells of PPARg þ /À mice (Setoguchi et al., 2001) . We therefore evaluated whether PPARg insufficiency promotes thyroid carcinogenesis in TRb PV/PV PPARg þ /À mice via the activation of the NF-kB signaling pathway. Consistent with the findings by others (Setoguchi et al., 2001; Wang et al., 2002; Fan et al., 2005) , PPARg insufficiency owing to the lack of one PPARg allele resulted in the significantly increased protein abundance of NF-kB in the thyroid of TRb PV/PV PPARg þ /À mice (lanes 10-12 versus lanes 7-9 and lanes 1-3; Figure 5a ). The functional consequence of the increased expression of NF-kB at the protein level is evident by the significantly increased cyclin D1 protein levels (lanes 10-12 versus 7-9 and 1-3; Figure 5b ). Cyclin D1 is a critical cell cycle regulator and is a direct NF-kB downstream target gene (Hinz et al., 1999; Biswas et al., 2000) . The marked elevated cyclin D1 levels in TRb PV/PV PPARg þ /À mice (lanes 10-12; Figure 5b ) suggest that activation of cyclin D1, in part, mediates the increased proliferation of thyrocytes. 
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In addition to its stimulatory effect on cell proliferation, another role for NF-kB in the initiation and/or progression of cancers is its antiapoptotic effect by the activation of genes involved in apoptosis (Suh and Rabson, 2004) . We therefore evaluated whether protein abundance of caspase-3, the critical gene converging signaling cascades leading to apoptosis, was altered. Figure 5c shows the significantly reduced protein levels of caspase-3 in the thyroids of TRb PV/PV PPARg þ /À mice (lanes 10-12 versus 7-9; Figure 5c ), signifying the reduced apoptotic activity in the thyroids of TRb mice. However, these two genotypes have significant differences in labeling intensity on a follicle-by-follicle basis, suggesting a synchrony of these events within each individual follicle. In both genotypes, follicular epithelial cells showed labeling in either the cytoplasm (arrowheads) or nuclei (arrows). These sections were PPARg þ /À mice (n ¼ 4-9) were dissected and compared in the same age groups. The data are presented as ratios of thyroid weight versus the body weight. The difference in the thyroid weight between TRb PV/PV mice with or without deletion of one PPARg allele is significant (Po0.05) as determined by ANOVA analysis. PPARg þ / þ mice. Consistent with this increased proliferation rate, cell cycle analysis indicated a shorter G 0 /G 1 phase accompanied by significant increases in the S and G 2 /M phases ( Figure 7B(a) ) and decreases in apoptosis ( Figure 7B(b) ). These findings further support the in vivo findings in that the PPARg insufficiency promotes tumor cell proliferation and reduces apoptosis.
Role of PPARc in thyroid carcinogenesis
In vivo, PPARg agonists delay the progression of thyroid carcinogenesis in TRb PV/PV mice The above in vivo findings predicted that activation of the PPARg signaling pathways by agonists could delay the pathological progression of follicular thyroid carcinoma in vivo. We therefore treated TRb PV/PV mice with rosiglitazone, a PPARg agonist that is now being used to treat diabetic patients. Figure 8A shows that treatment of TRb PV/PV mice with rosiglitazone led to a 40% reduction of thyroid growth (no treatment: 128716 mg, n ¼ 11; with treatment: 79711 mg, n ¼ 9 for Po0.03). Importantly, Figure 8B shows that the occurrence of capsular invasion, a hallmark of malignancy, was significantly lower in mice treated with rosiglitazone than in control mice (Po0.01). Although no statistically significant difference was observed for the occurrence of vascular invasion between treated and untreated mice, a trend of decreased frequency of 
Y Kato et al occurrence was apparent in mice treated with rosiglitazone. Remarkably, although 20% of mice that had not received rosiglitazone developed metastasis in the lung, no metastasis was detected in TRb PV/PV mice treated with rosiglitazone. These results suggest that activation of the PPARg signaling pathway delays the progression of thyroid cancer in TRb PV/PV mice. Histopathological examination revealed that the hyperplastic thyroids in untreated mice had extensive hyperplasia of follicular epithelia, as shown at low ( Figure 8C(a) ) and high ( Figure 8C(c) ) magnification. Similar fields from mice treated with rosiglitazone (low magnification, Figure 8C (b); high magnification, Figure  8C (d)) showed epithelial cellular damage, including cell and nuclear swelling (arrowhead, panel d) and nuclear chromatin condensation typical of apoptotic cell death (arrows, panel d). To be certain that delayed pathological progression is the consequence of the activation of the PPARg signaling pathway, we examined the effect of rosiglitazone on the mRNA expression of PPARg downstream genes. Rosiglitazone did not change the expression of PPARg (Figure 9a ), but it clearly activated the expression of its direct target gene, LpL (Figure 9b ), indicating activation of the PPARg signaling pathway by rosiglitazone. The expressions of the NF-kB (Figure 9c ) and cyclin D1 (Figure 9d ) were significantly reduced, but the expression of caspase-3 (Figure 9e) was not significantly altered. At the protein level, however, caspase-3 was increased (data not shown). These gene expression patterns further support the idea that activation of the PPARg signaling pathway mediates the delayed carcinogenesis of thyroid cancer.
Discussion
Increasing lines of evidence have suggested the important role of PPARg in human cancers. In vitro studies have shown that activation of the PPARg signaling pathway by ligands inhibits growth and induces differentiation and apoptosis in cultured cells of leukemia (Asou et al., 1999) , bladder cancer (Guan et al., 1999) , choriocarcinoma (Keelan et al., 1999) , prostate cancer (Kubota et al., 1998) , pancreatic carcinoma (Motomura et al., 2000) , chondrosarcoma (Nishida et al., 2002) , colon cancer (Sarraf et al., 1998) , gastric cancer (Takahashi et al., 1999) and lung cancer (Tsubouchi et al., 2000) . As the discovery of the PAX8-PPARg fusion gene in human follicular thyroid carcinoma and the demonstration of loss of PPARg transcription activity in the PAX8-PPARg fusion gene , there has been great interest in understanding the role of PPARg in the development and progression of follicular thyroid carcinoma. In vitro cell-based studies have shown that troglitazone induces antiproliferation and apoptosis in several human thyroid cell lines (Ohta et al., 2001; Park et al., 2005) , but TRb PV/PV mice provide the first opportunity to address this question in vivo. The present study showed that treatment of TRb PV/PV mice in vivo with PPARg ligands inhibited thyrocyte proliferation and induced apoptosis. We further demonstrated that PPARg insufficiency in TRb PV/PV PPARg þ /À mice promoted thyroid carcinogenesis. These findings strongly suggest that PPARg is a tumor suppressor in follicular thyroid cancer. Importantly, these findings are consistent with the findings that the loss of the PPARg activity when it is fused to PAX8 is associated with the development of human follicular thyroid cancer . TRb PV/PV mice also allowed us to dissect PPARg downstream molecular pathways that affect thyroid carcinogenesis in vivo. We found that the tumor suppressor effect of PPARg occurs via inhibition of cell proliferation and induction of apoptosis (Figure 10 ). The former is mediated by repression of cyclin D1 
PPARg
þ /À mice. Western blot analysis was carried out as described in the Materials and methods for NF-kB (a), cyclin D1 (b), caspase-3 (c) and a-tubulin as loading controls (d). Representative results from three mice are shown and the genotypes are marked. After the intensities of bands were quantified and normalized against the loading controls shown in (d), the fold changes are indicated to reflect the differences in reference to the wild-type mice. The significant differences are as indicated (mean7s.e.m., n ¼ 3; *Po0.05; **Po0.01; ***Po0.001). The differences in the protein levels between TRb PV/PV PPARg þ /À mice and TRb PV/PV PPARg þ / þ (lanes 10-12 and lanes 7-9, respectively) are also statistically significant (Po0.05).
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expression and the latter is mediated by activation of caspase-3. We previously found that in TRb PV/PV mice, PV constitutively activated the expression of cyclin D1 via tethering to the cyclin D1 promoter through binding to the c-AMP response element binding protein (Furumoto et al., 2005) . In the present study, we discovered that reduced expression of PPARg led to the activation of the NF-kB signaling pathway. NF-kB is known to bind to its DNA binding site in the promoter of cyclin D1 to activate the expression of cyclin D1 (Joyce et al., 1999) . Thus, these two mechanisms converge to result in a significantly increased cyclin D1 expression to promote thyrocyte proliferation. Activation of the NF-kB signaling pathway by the reduced expression of PPARg also led to decreased apoptosis in TRb PV/PV mice. Activation of several NF-kB downstream target genes is known to inhibit caspase activation and suppress the apoptotic response (Baud and Karin, 2001 ). Indeed, we found decreased expression of caspase-3 in TRb PV/PV mice lacking one allele of PPARg (TRb PV/PV PPARg þ /À mice). Thus, both increased proliferation and decreased apoptosis mediated by a reduced expression of PPARg contribute to promoting thyroid carcinogenesis in TRb PV/PV mice. Long-term stimulation of the thyroid by TSH has been implicated in a more frequent incidence of thyroid cancer (Cooper et al., 1981) . Recent evidence, however, does not support the role of TSH as an initiator of follicular thyroid carcinoma (Ledent et al., 1992; Mazzaferri, 1993; Michiels et al., 1994; Zeiger et al., 1997) . The identification of multiple pathways associated with thyroid carcinogenesis suggests that additional genetic changes need to occur for the transformation of the TSH-stimulated hyperproliferative thyroid cells to cancer cells (Ying et al., 2003a; Chevillard et al., 2004 mice, but differed with significantly reduced labeling intensity on a follicle-by-follicle basis, suggesting a synchrony of these events within each individual follicle. These sections were used for morphometric quantitation of either the total area of cleaved caspase-3 signal, or by counting the number of labeled nuclei over equal areas. The data showing reduced labeling in TRb PV/PV PPARg þ /À mouse thyroids are as shown in the Results (all magnifications ¼ Â 400).
PPARg agonists have been shown to inhibit growth and induce apoptosis of several cultured human thyroid tumor cells (Ohta et al., 2001; Klopper et al., 2004 ). The present study shows that treatment of TRb PV/PV mice with a thiazoledinedione PPARg agonist, rosiglitazone, delays the progression of thyroid carcinogenesis in vivo. Therefore, PPARg is a critical modifier for thyroid carcinogenesis. One of its agonists, rosiglitazone, is currently being used to treat patients with type II diabetes mellitus. Small-scale clinical trials have been conducted using another thiazoledinedione PPARg agonist, troglitazone, to treat liposarcoma (Demetri et al., 1999) and prostate cancer . In the three patients with liposarcoma, there was a marked reduction in immunohistochemical expression of Ki-67 (a marker for cell proliferation) and induced differentiation (Demetri et al., 1999) . In the 41 patients with prostate cancer, the prostate-specific antigen levels were decreased in eight patients . These two clinical trials suggest the potential therapeutic application in these cancers. The present study shows that rosiglitazone can significantly decrease thyroid growth and induce apoptosis in a mouse model of follicular thyroid carcinoma. Therefore, rosiglitazone can be tested as a potential therapeutic agent for the treatment of human follicular thyroid carcinoma.
Materials and methods

Experimental animals
All animal experiments were performed according to protocols approved by the Animal Care and Use Committee at NIH. The mice harboring the TRbPV gene were prepared and genotyped as described previously (Kaneshige et al., 2000) . Two-month-old male TRb PV/PV mice were fed an AIN-76A diet (Bio Serve, Frenchtown, NJ, USA) mixed with (n ¼ 14) or without (n ¼ 13) rosiglitazone (20-80 mg/kg/day; Avandia, GlaxoSmithKline, Research Triangle Park, NC, USA) for 7-8 months. TRb PV/PV PPARg þ /À mice were prepared by crossing PPARg þ /À mice (a generous gift of Frank Gonzalez, NCI) with TRb PV/ þ mice. Littermates with similar genetic background were used in the experiments. Moribund mutant mice and controlled wild-type littermates were euthanized to harvest thyroids for weighing, histological analysis and extraction of total RNA and protein.
Quantitative RT-PCR A SYBR Quantitative RT-PCR kit was used to determine mRNA expression of genes of interest according to the manufacturer's protocol (Sigma-Aldrich, St Louis, MO, USA). The analysis was carried out as described previously (Ying et al., 2003b) . The primers used in this study were as follows:
NF-kB1, forward primer -5 0 -TTGAAGTGATCCAGGC-3 0 , reverse primer -5 0 -GGATTCGCTTTGCCTTCCTCCT-3 0 ; caspase-3, forward primer -5 0 -GGAGCTGGACTGTGGC 
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0 , reverse primer -5 0 -CAGTTCTTTCGTGAGCAT GGA-3 0 . Primer sequences for PPARg, LpL, cyclin D1 and GAPDH have been described previously (Ying et al., 2003a, b; Kato et al., 2004) .
Establishment of TRb
PV/PV thyroid tumor-derived cell lines Thyroid lobes were dissected aseptically from the trachea and weighed. A small portion of the lobes was fixed in 10% neutral-buffered formalin and subsequently embedded in paraffin. Five-mm-thick sections were prepared and stained with hematoxylin for histological analysis to confirm the occurrence of follicular thyroid carcinoma.
Thyroid tumor cell lines were prepared according to Jeker et al. (1999) with minor modifications. After enzymatic digestion, the cell pellet was resuspended in 1 ml of cultured medium and pipetted up and down with a P-1000 pipette and centrifuged for 3 min at 700 g. This process was repeated three times to disperse the cells. The culture medium was prepared as follows: Nu-Serum IV (BD Biosciences, Bedford, MA, USA) was diluted 2.5 times with F-12 medium. This diluted Nu-Serum IV was supplemented with somatostain at a concentration of 10 ng/ml, with glycyl-L-histidyl-L-lysine 
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Y Kato et al acetate at a concentration of 2 ng/ml, with TSH at a concentration of 5 mIU/ml and with antibiotic-antimycotic (Gibco, Grand Island, NY, USA) at a concentration of 200 U/ ml. Subconfluent cultures were expanded by treatment with trypsin-EDTA. Media and all hormones were from SigmaAldrich.
Determination of tumor cell growth and cell cycle analysis Cultured thyroid tumor cells, as described above, were synchronized to G 0 phase in 0.1% Nu-Serum for 30 h and re-seeded (4 Â 10 4 cells) in 12-well cell culture cluster (Corning, Corning, NY, USA). The cell numbers were determined in triplicates daily by using a Beckman Coulter Z Series (Beckman Coulter Inc., Fullerton, CA, USA).
For cell cycle analysis, thyroid tumor cells were treated with trypsin-EDTA, washed with PBS and fixed with ice-cold 70% ethanol at 41C for 18 h. After centrifugation (200 g, 41C, 5 min), the cell pellet was resuspended in PBS containing 1 U/ml DNAse-free RNAse (Roche, Indianapolis, IN, USA) for 20 min. Cells were treated with propidium iodide (30 mg/ml; Molecular Probes Inc., Eugene, OR, USA) in the dark for 30 min. DNA content was determined by flow cytometry using a FACSCalibur (BD Biosciences, San Jose, CA, USA). Analysis was carried out using ModFit software (Verity Software House Inc., Topsham, ME, USA).
Hormone assays TT4 and TT3 were determined by using a Clinical Assayt GammaCoatt T3 or T4 125 I RIA Kit (DiaSolin, Stillwater, MN, USA), according to the manufacturer's instructions. Serum TSH levels were measured as described previously (Kato et al., 2004; Furumoto et al., 2005) .
Western blot analysis
Thyroids dissected from mice were washed with PBS (-) and homogenized on ice in cell lysis buffer containing 50 mM Tris, 100 mM NaCl, 0.1% Triton X-100, 0.2 mM okadaic acid, 100 mM NaF, 2 mM Na 3 VO 4 and proteinase inhibitor tablet (Completet Mini EDTA-free; Roche), followed by incubation of the tissue lysate on ice for 10 min with occasional vortexing. After centrifugation and protein determination, lysates (50 mg) were analysed by SDS-PAGE and the Western blot analysis was carried out as described in Furumoto et al. (2005) . The antibodies (cyclin D1 (sc-450; 1:100 dilution); PPARg (sc-7196; 1:100 dilution); caspase-3 (sc-7148; 1:200 dilution); NF-kB (sc-372; 1:200 dilution)) were all from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). For control of protein loading, the blots were stripped and re-reacted with anti-a-tubulin antibody (No. T6199, 1:10,000 dilution; Sigma Inc.).
Histological analysis
Thyroid gland, lung, heart and lymph nodes were dissected and embedded in paraffin. Five-mm-thick sections were prepared and stained with hematoxylin and eosin (H&E). For each animal, a single random section through the thyroid (usually both lobes) and the lung and heart were examined. For thyroids, morphological evidence in that single section of hyperplasia, capsular invasion, vascular invasion and anaplasia were routinely counted. Hyperplasia was generally diffuse throughout the gland. Evidence of any of these changes in any section was counted as positive for that change. On average, in those cases with capsular invasion and/or vascular invasion, these morphological changes were seen in multiple locations (usually two or three) in any one thyroid section. Anaplasia was rarer, and was usually only seen in single foci. The presence of a single microscopic focus of metastatic follicular carcinoma in the lung was counted as positive for metastasis in that animal.
Immunohistochemistry
Cleaved caspase-3 was detected via immunohistochemistry in paraffin sections by standard methods. Briefly, sections were processed by antigen retrieval using Antigen Unmasking Solution (Vector Laboratories Inc., Burlingame, CA, USA) and incubation at 951C for 1 h. The sections were then blocked using 1% BSA-PBS for 30 min, followed by sequential incubations in 1:100 rabbit anti-cleaved caspase-3 (Cell Signaling Technology, Beverly, MA, USA), followed by goat anti-rabbit IgG conjugated to horseradish peroxidase (25 mm/ ml in BSA-PBS) for 30 min at room temperature. Peroxidase was detected using diaminobenzidine-peroxide substrate in PBS, and the sections were counterstained with hematoxylin. The method used to immunostain PPARg was the same except for the use of anti-PPARg antibody (1:100 dilution) (Santa Cruz Biotechnology Inc.; sc-7196).
Morphometric quantitation of immunoperoxidase labeling of cleaved caspase-3
To measure peroxidase labeling intensity, bright field digital images were captured from sections of thyroids labeled for cleaved caspase-3 using peroxidase (15 sections of each sample using a Â 4 objective) such that the entire section was covered by the captured images (3.6 million square microns). Each image contained 6 million pixels. Altogether, five TRb PV/PV PPARg þ / þ mice and five TRb PV/PV PPARg þ /À mice were examined. With Adobe Photoshop, a defined threshold was chosen and the 'magic wand' tool was used to select all similar areas with the same color characteristic of peroxidase reaction product. The total area in thousands of pixels was measured for each mouse. These data were expressed as peroxidase-labeled area in K-pixels per mouse. In addition to quantifying the labeling intensity, we also counted the number of positive labeled nuclei in thyroids. Individual fields were viewed directly using a Â 20 objective, and the number of nuclei labeled per field was counted while covering the entire section surface fieldby-field. This was performed for two mice in each genotype. These data are expressed as the number of labeled nuclei per Â 20 field.
Statistical analysis
All data are expressed as mean7s.e.m. Statistical analysis was performed with the use of ANOVA, and Po0.05 was considered significant unless otherwise specified. StatView 5.0 was used to perform Kaplan-Meier cumulative survival analysis (Lee, 1992) , and Student's t-test using odds ratios and Fisher's exact probability test were used to analyse the data of pathological progression (Fleiss, 1981) . GraphPad PRISM 4.0a (GraphPad Software Inc., San Diego, CA, USA) was used for log-rank testing for statistical significance.
